Silver Ring Value Partners' Q3 2024 investor letter discusses the portfolio's -9.2% return compared to market indices. They highlight Jazz Pharmaceuticals plc as a strong investment due to its product offerings, with a 3.97% one-month return and a $117.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing